Genmab A/S has solidified its leadership in oncology by leveraging proprietary antibody platforms such as DuoBody and HexaBody, enabling innovative bispecific antibodies like epcoritamab (EPKINLY). Its commercial success is augmented through strategic collaborations with AbbVie, Pfizer, and others, supporting robust royalty streams and product sales. However, Genmab’s significant indebtedness imposes restrictive covenants that constrain financial flexibility, requiring a delicate balance between aggressive R&D investment and operational discipline. The company’s diverse late-stage pipeline and recent trial successes underscore potential for sustained innovation-led growth, tempered by regulatory and legal hurdles inherent to biotechnology development.